BACKGROUND: Psoriasis is one of the most prevalent chronic inflammatory diseases, affecting approximately 2 million people in Germany. METHODS: Selective literature review taking into account the German S1 and S3 guidelines for the treatment of this condition. RESULTS AND CONCLUSIONS: Psoriasis is a very troublesome disease with a high economic impact. The disease often persists for life, and the patient has an increased risk of cardiovascular diseases and their complications. One out of five patients develops psoriatic arthritis. The clinical picture of psoriasis is highly variable with regard to lesional characteristics and the severity of disease. To improve the management of psoriasis the guidelines must be followed and all appropriate topical and systemic treatment options must be tried, with clearly defined treatment goals. The spectrum of established systemic treatments for psoriasis has been extended by the biologics. These can be used to achieve a good skin status and a clear-cut improvement in quality of life even in patients who do not--or no longer--respond adequately to conventional therapies.
BACKGROUND:Psoriasis is one of the most prevalent chronic inflammatory diseases, affecting approximately 2 million people in Germany. METHODS: Selective literature review taking into account the German S1 and S3 guidelines for the treatment of this condition. RESULTS AND CONCLUSIONS:Psoriasis is a very troublesome disease with a high economic impact. The disease often persists for life, and the patient has an increased risk of cardiovascular diseases and their complications. One out of five patients develops psoriatic arthritis. The clinical picture of psoriasis is highly variable with regard to lesional characteristics and the severity of disease. To improve the management of psoriasis the guidelines must be followed and all appropriate topical and systemic treatment options must be tried, with clearly defined treatment goals. The spectrum of established systemic treatments for psoriasis has been extended by the biologics. These can be used to achieve a good skin status and a clear-cut improvement in quality of life even in patients who do not--or no longer--respond adequately to conventional therapies.
Authors: L Naldi; F Parazzini; A Brevi; A Peserico; C Veller Fornasa; G Grosso; E Rossi; P Marinaro; M M Polenghi; A Finzi Journal: Br J Dermatol Date: 1992-09 Impact factor: 9.302
Authors: Shigetoshi Sano; Keith Syson Chan; Steve Carbajal; John Clifford; Mary Peavey; Kaoru Kiguchi; Satoshi Itami; Brian J Nickoloff; John DiGiovanni Journal: Nat Med Date: 2004-12-12 Impact factor: 53.440
Authors: C Blome; A Costanzo; E Dauden; C Ferrandiz; G Girolomoni; R Gniadecki; L Iversen; A Menter; K Michaelis-Wittern; A Morita; H Nakagawa; K Reich; M Augustin Journal: Qual Life Res Date: 2015-10-03 Impact factor: 4.147
Authors: Sofia Tsiori; Natalia Rompoti; Konstantinos Kontoangelos; Christos Papageorgiou; Charalabos Papageorgiou; Alexander Stratigos; Dimitrios Rigopoulos Journal: Int J Environ Res Public Health Date: 2022-03-29 Impact factor: 3.390